Key result
Neuromuscular-blocking agents are supported for short-course (<48 h) paralysis in patients with moderate-to-severe acute respiratory distress syndrome and PaO2/FiO2 ratio <150.
Why the study?
Neuromuscular-blocking agents are a cornerstone in managing critically ill patients, making proper knowledge and evidence-based use fundamental.
Neuromuscular-blocking agents are a cornerstone in managing critically ill patients, with evidence supporting short courses (<48 h) in moderate-to-severe ARDS.
Neuromuscular-blocking agents (NMBAs) are a cornerstone in the management of critically ill patients. There is evidence supporting short course (<48 h) of paralysis for patients with moderate-to-severe acute respiratory distress syndrome with PaO2/FiO2 ratio <150. Proper knowledge of these agents and their evidence-based use is fundamental. Health-care providers can play an important role in the regulation and the use of NMBAs in critically ill patients.
No takes yet. Share an insight, caveat, or question.
Harbi et al. (2019) conducted a review in Acute respiratory distress syndrome in critically ill patients. Neuromuscular-blocking agents (NMBAs) was evaluated. Neuromuscular-blocking agents are supported for short-course (<48 h) paralysis in patients with moderate-to-severe acute respiratory distress syndrome and PaO2/FiO2 ratio <150.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: